316 related articles for article (PubMed ID: 26755831)
1. Long-term survival of nasopharyngeal carcinoma patients with Stage II in intensity-modulated radiation therapy era.
Guo Q; Lu T; Lin S; Zong J; Chen Z; Cui X; Zhang Y; Pan J
Jpn J Clin Oncol; 2016 Mar; 46(3):241-7. PubMed ID: 26755831
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcomes of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma treated with IMRT: a retrospective study.
Su Z; Mao YP; Tang J; Lan XW; OuYang PY; Xie FY
Tumour Biol; 2016 Apr; 37(4):4429-38. PubMed ID: 26499947
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.
Qiu WZ; Huang PY; Shi JL; Xia HQ; Zhao C; Cao KJ
Chin J Cancer; 2016 Jan; 35():2. PubMed ID: 26739148
[TBL] [Abstract][Full Text] [Related]
4. Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost.
Ou X; Zhou X; Shi Q; Xing X; Yang Y; Xu T; Shen C; Wang X; He X; Kong L; Ying H; Hu C
Oncotarget; 2015 Nov; 6(35):38381-97. PubMed ID: 26485757
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of induction chemotherapy in the treatment of stage II nasopharyngeal carcinoma in intensity modulated radiotherapy era.
Li PJ; Mo HY; Luo DH; Hu WH; Jin T
Oral Oncol; 2018 Oct; 85():95-100. PubMed ID: 30220326
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcomes of early-stage nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy alone.
Su SF; Han F; Zhao C; Chen CY; Xiao WW; Li JX; Lu TX
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):327-33. PubMed ID: 21035959
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus neoadjuvant chemotherapy plus concurrent chemoradiotherapy for ascending or descending types of nasopharyngeal carcinoma: A retrospective study.
Lin Q; Lu L; Wang X; Lin Y; Chen Y; Chen H; Chen S; Lin S; Zhang Y; Zheng P; Chen X
Am J Otolaryngol; 2022; 43(1):103193. PubMed ID: 34509080
[TBL] [Abstract][Full Text] [Related]
8. Intensity-modulated radiation therapy without concurrent chemotherapy for stage IIb nasopharyngeal cancer.
Tham IW; Lin S; Pan J; Han L; Lu JJ; Wee J
Am J Clin Oncol; 2010 Jun; 33(3):294-9. PubMed ID: 20395788
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of lobaplatin combined with 5-fluorouracil as first-line induction chemotherapy followed by lobaplatin-radiotherapy in locally advanced nasopharyngeal carcinoma: preliminary results of a prospective phase II trial.
Ke LR; Xia WX; Qiu WZ; Huang XJ; Yang J; Yu YH; Liang H; Liu GY; Ye YF; Xiang YQ; Guo X; Lv X
BMC Cancer; 2017 Feb; 17(1):134. PubMed ID: 28202000
[TBL] [Abstract][Full Text] [Related]
10. Role of sequential chemoradiotherapy in stage II and low-risk stage III-IV nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: A propensity score-matched analysis.
Xu C; Sun R; Tang LL; Chen L; Li WF; Mao YP; Zhou GQ; Guo R; Lin AH; Sun Y; Ma J; Hu WH
Oral Oncol; 2018 Mar; 78():37-45. PubMed ID: 29496056
[TBL] [Abstract][Full Text] [Related]
11. Survival benefit of adding chemotherapy to intensity modulated radiation in patients with locoregionally advanced nasopharyngeal carcinoma.
Ji X; Xie C; Hu D; Fan X; Zhou Y; Zheng Y
PLoS One; 2013; 8(2):e56208. PubMed ID: 23441169
[TBL] [Abstract][Full Text] [Related]
12. Effects of induction docetaxel, platinum, and fluorouracil chemotherapy in patients with stage III or IVA/B nasopharyngeal cancer treated with concurrent chemoradiation therapy: Final results of 2 parallel phase 2 clinical trials.
Kong L; Zhang Y; Hu C; Guo Y; Lu JJ
Cancer; 2017 Jun; 123(12):2258-2267. PubMed ID: 28192641
[TBL] [Abstract][Full Text] [Related]
13. T4/N2 classification nasopharyngeal carcinoma benefit from concurrent chemotherapy in the era of intensity-modulated radiotherapy.
Xie R; Xia B; Zhang X; Hu W; Zhao R; Xie C; Wang J; Zhang N; Wu S
Oncotarget; 2016 Dec; 7(49):81918-81925. PubMed ID: 27636993
[TBL] [Abstract][Full Text] [Related]
14. Long-term treatment outcome of recurrent nasopharyngeal carcinoma treated with salvage intensity modulated radiotherapy.
Hua YJ; Han F; Lu LX; Mai HQ; Guo X; Hong MH; Lu TX; Zhao C
Eur J Cancer; 2012 Dec; 48(18):3422-8. PubMed ID: 22835782
[TBL] [Abstract][Full Text] [Related]
15. Survival analysis of patients with advanced-stage nasopharyngeal carcinoma according to the Epstein-Barr virus status.
Peng H; Chen L; Zhang Y; Guo R; Li WF; Mao YP; Tan LL; Sun Y; Zhang F; Liu LZ; Tian L; Lin AH; Ma J
Oncotarget; 2016 Apr; 7(17):24208-16. PubMed ID: 27008701
[TBL] [Abstract][Full Text] [Related]
16. The role of concurrent chemotherapy for stage II nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A systematic review and meta-analysis.
Liu F; Jin T; Liu L; Xiang Z; Yan R; Yang H
PLoS One; 2018; 13(3):e0194733. PubMed ID: 29566078
[TBL] [Abstract][Full Text] [Related]
17. Survival of stage II nasopharyngeal carcinoma patients with or without concurrent chemotherapy: A propensity score matching study.
Liu DH; Zhou XY; Pan YG; Chen S; Ye ZH; Chen GD
Cancer Med; 2020 Feb; 9(4):1287-1297. PubMed ID: 31859464
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of intensity-modulated radiotherapy alone versus intensity-modulated radiotherapy plus chemotherapy for treatment of intermediate-risk nasopharyngeal carcinoma.
Aftab O; Liao S; Zhang R; Tang N; Luo M; Zhang B; Shahi S; Rai R; Ali J; Jiang W
Radiat Oncol; 2020 Mar; 15(1):66. PubMed ID: 32178698
[TBL] [Abstract][Full Text] [Related]
19. Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial.
Chen QY; Wen YF; Guo L; Liu H; Huang PY; Mo HY; Li NW; Xiang YQ; Luo DH; Qiu F; Sun R; Deng MQ; Chen MY; Hua YJ; Guo X; Cao KJ; Hong MH; Qian CN; Mai HQ
J Natl Cancer Inst; 2011 Dec; 103(23):1761-70. PubMed ID: 22056739
[TBL] [Abstract][Full Text] [Related]
20. Lobaplatin combined with docetaxel neoadjuvant chemotherapy followed by concurrent lobaplatin with intensity-modulated radiotherapy increases the survival of patients with high-risk lymph node positive nasopharyngeal carcinoma.
Zhang S; Lin S; Hu L
J BUON; 2016; 21(1):161-7. PubMed ID: 27061544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
